Search results
Xyphos and Poseida to develop allogeneic cell therapies for cancer
Pharmaceutical Technology via Yahoo Finance· 9 hours agoThe parties will combine their cell therapy platforms to create a new convertible chimeric antigen...
Astellas adds to ‘off-the-shelf’ cell therapy capabilities with Poseida deal
BioPharma Dive via Yahoo Finance· 1 day agoAstellas Pharma is betting again on cell therapy, announcing Wednesday a deal with Poseida...
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop...
The Record Gazette· 18 hours agoPoseida is advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases.
Astellas and Poseida join forces for cancer cell therapy By Investing.com
Investing.com· 18 hours agoAstellas Pharma Inc. (TSE: 4503) and Poseida Therapeutics, Inc. (NASDAQ: PSTX) have entered a...
Anonymous donor gives Valley Children’s $15 million to fund cancer treatment, hospital says
The Fresno Bee· 2 hours agoA $15 million donation to Valley Children’s Hospital from an anonymous donor will be used to create...
Cytokine Release Syndrome: What to Know
Verywell Health via Yahoo News· 20 minutes agoCytokine release syndrome (CRS) occurs when the immune system responds to infection or immunotherapy drugs more aggressively than it should. Learn more...
OBiO Technology will showcase at American Society of Gene & Cell Therapy
FOX 4 Kansas City· 4 days agoOBiO Technology (Shanghai) Corp., Ltd. (OBiO, 688238.SH), a world leading contract development and...
Replay wins IND clearance for PRAME T cell cancer therapy
Clinical Trials Arena via Yahoo Finance· 1 day agoGenome writing company Replay Bio has had its investigational new drug (IND) application cleared by...
Iovance Biotherapeutics Inc (IOVA) Stock Records 44.94% Quarterly Movement – News Heater
NewsHeater· 3 days agoThe stock of Iovance Biotherapeutics Inc (IOVA) has gone up by 6.27% for the week, with a -18.83% drop in the past month and a 44.94% rise in the past quarter. The volatility ratio for the week ...
Astellas hitches a ride in Poseida's convertible for $50M cell therapy collaboration
FierceBiotech· 1 day agoThe companies have signed an agreement, via Astellas’ subsidiary Xyphos Biosciences, to develop two ...